Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. It has discovered a pipeline of oral nonpeptide chemical entities that target peptide G protein coupled receptors (GPCRs) to treat a rare endocrine disease. Its product candidates include paltusotine, CRN04777 and CRN04894. Its paltusotine is in clinical development for the treatment of acromegaly and neuroendocrine tumors. CRN04777 is an investigational, oral, nonpeptide somatostatin receptor type 5 (SST5), agonist designed for the treatment of congenital hyperinsulinism (HI). CRN04894 is an investigational, oral, nonpeptide product candidate designed for the treatment of diseases caused by excess adrenocorticotrophic hormone (ACTH), including Cushings disease, congenital adrenal hyperplasia (CAH), and Ectopic ACTH Syndrome (EAS).
Buy US stocks in Australia starting with CRNX. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in CRNX
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.